Citigroup’s Liminatus Pharma LIMN Stock Holding History

Citigroup’s Portfolio LIMN Stock Details LIMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-135	Closed	-$1.16K	–	6395
2026 Q1	$1.16K	Buy	+135	New	+$3.6K	﹤0.01%	5469
2025 Q4	–	Hold	0	–	–	–	6009

Other funds holding LIMN

CCA

Cygnus Capital Advisors Atlanta, Georgia $147M AUM

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup's LIMN Position: Q2 2026 in Review

Citigroup sold out of Liminatus Pharma (LIMN) in Q2 2026, closing a stake of 135 shares — an estimated $1.16K sold.

Citigroup first reported a position in LIMN in Q1 2026 and held it in 1 quarter. The position peaked at $1.16K in Q1 2026. 14 funds tracked by Wall St. Rank hold LIMN as of Q2 2026.

Citigroup reported no remaining Liminatus Pharma position as of Q2 2026 after selling out during the quarter.
Citigroup sold 135 Liminatus Pharma shares in Q2 2026, an estimated $1.16K.
Citigroup first reported a position in Liminatus Pharma in Q1 2026 and held it in 1 quarter.
Citigroup's Liminatus Pharma position peaked at $1.16K in Q1 2026.
14 funds tracked by Wall St. Rank held Liminatus Pharma as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.